@FierceBiotech: Sanofi grabs a discovery pact with gut expert Ardelyx in $198M deal. Story | Follow @FierceBiotech
@JohnCFierce: Have to wonder about these bullish peak sales forecasts on dulaglutide. Are patients ready to switch based on easier dosing? | Follow @JohnCFierce
@DamianFierce: InterMune trading up 150% premarket. Here's why. | Follow @DamianFierce
@EmilyMFierce: Global tuberculosis R&D takes hit with AstraZeneca site closure. News | Follow @EmilyMFierce
> Sweden's InDex Pharmaceuticals says it has raised $20 million in a new round led by NeoMed. InDex plans to report Phase III data on Kappaproct, which is being developed for the treatment of severe ulcerative colitis. Release
> GlaxoSmithKline ($GSK) is kicking off its second contest for academic drug hunters, calling for research proposals in the 2014 Discovery Fast Track Challenge, through which investigators have the chance to translate their early-stage research into GSK development programs. Release
> AstraZeneca's VP of global communications, Neil McCrae, is off to join the Royal Mail. Story
> Cambridge, MA-based Verastem ($VSTM) says it has acquired the license to VS-4718 held originally by Poniard Pharmaceuticals. Release
> New York's Dipexium Pharmaceuticals has set terms for a $30 million IPO, planning to use the haul to develop a late-stage antibiotic treatment for diabetic foot ulcers. More
@FierceMedDev: Boston Scientific is trying to nip at Medtronic's heels, as far as neuromodulation goes. Has it been successful? Report | Follow @FierceMedDev
@MarkHFierce: St. Jude Medical may not be #1 in neuromodulation, but it is pushing hard to get there. Report | Follow @MarkHFierce
@MichaelGFierce: An FDA panel wants to change iontophoresis drug delivery regulation. More (reg. req) | Follow @MichaelGFierce
@EmilyWFierce: Practice Fusion is teaming up with medical device companies to provide "real-time" accounts of patient health. Article | Follow @EmilyWFierce
> Volcano moves the bar a notch higher for 2014 as restructuring continues. Story
> MIT, Apple and others help shape Quanttus' wearable clinical monitoring tech. More
> India moves closer to approving key medical device legislation. News
Pharma News
@FiercePharma: AbbVie, Amgen and Roche most vulnerable to biosim rivals, Moody's says. More | Follow @FiercePharma
@TracyStaton: With new study, Pfizer closes in on $1B-plus sales boost for #Prevnar vaccine. More | Follow @TracyStaton
@EricPFierce: No sooner does Commish Hamburg return from India than the FDA reveals a new warning letter about data faking there. Article | Follow @EricPFierce
@CarlyHFierce: Vivus beats the street on licensing payments, but investors aren't fooled. Story | Follow @CarlyHFierce
> U.K. drug reviewers slam BMS' melanoma blockbuster but bless J&J's diabetes pill. More
> The Vasella era ends as Novartis says goodbye to his policies--or is it good riddance? News
Pharma Manufacturing News
> The FDA catches another Indian drugmaker falsifying data. News
> Ranbaxy halts production at 2 plants to tackle its regulatory mess. Story
> The FDA has expanded its equivalency testing of generics. Article
> GSK vows to maintain soccer fields in new U.K. plant. Story
> Hamburg says FDA's focus on India reflects its place in the global supply chain. Story
> Pfizer and MIT are looking for more efficient biologics manufacturing. Brief
Biotech Research News
> Gene therapy regenerates damaged tissue in pigs after heart attack. Story
> Reprogrammed skin cells could provide a way to regenerate liver tissue. Article
> Global tuberculosis R&D takes hit with AstraZeneca site closure. News
> HPV-like vaccine guards against skin tumors in mice. Article
> DOD selects Bavarian Nordic to develop vaccine against biological threats. News
> Berg, Parkinson's Institute partner to find biomarkers. Brief